VA-REGULA
Regula's expansion has been notably significant in three key markets: the United States, the United Arab Emirates, and Great Britain, which collectively account for over 35% of its global user base. The growth rates in these regions have been particularly impressive: United States – 216%; United Arab Emirates – 321%; United Kingdom – 95%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240228514546/en/
Growth Trends: Regula User Expansion & Verification Scenarios in Key Markets (Graphic: Business Wire)
Not only do these figures highlight Regula's increasing prominence in these markets, but also underscore the global trust in the company’s technologies for secure and reliable identity verification. What sets Regula apart is its independence from third-party solutions, with all technologies developed internally. Regula offers a single-vendor solution for identity verification, combining biometric (Regula Face SDK) and document (Regula Document Reader SDK) checks with advanced authenticity validation, as well as forensic tools for detailed analysis.
The rise of full authenticity checks
The results of the survey conducted by Regula at the beginning of 2023 highlight an increase in identity fraud. The most prevalent form of fraudulent activity experienced by organizations was the use of fake or modified physical documents. 26% of small and medium businesses (SMBs) and 38% of enterprises experienced more than 50 identity fraud incidents during the previous year. The cost was also significant, with 64% of all businesses reporting losses of at least $120,000, and 37% of the world’s largest businesses reporting losses of at least $480,000.
In response to the evolving landscape of digital fraud, Regula has intensively focused on enhancing its techniques aimed at validating document authenticity. Its advanced authentication method facilitates verification of ID security features, as well as document liveness validation. This processing scenario has seen astounding growth rates in the United States (367%), United Arab Emirates (400%), and United Kingdom (86%).
Strengthening security with cross-validation
Regula also reports a steady increase in the adoption of its cross-validation checks, which provide maximum confidence in the consistency and authenticity of identity document data. These checks help ensure data integrity by cross-comparing personal details or biometric information provided on an identification document.
Growth rates in this area are equally remarkable: United States – 156%, United Arab Emirates – 257%, United Kingdom – 244%.
Regula's extensive proprietary database, which includes more than 13,600 document templates from 249 countries and territories and supports over 138 languages, is central to the success of these checks.
Diverse user engagement across platforms
A key advantage of Regula's identity verification solutions is their compatibility across various platforms, allowing for seamless ID verification processes, whether on mobile, web, desktop, or passport reading devices.
The company's success is demonstrated through its provision of hardware and software solutions for digital identity verification, serving a worldwide network of more than 1,000 organizations and 80 border control authorities. Some of the world's most innovative and reputable organizations rely on Regula’s hardware and software solutions to solve a range of challenges. For example:
- UBS, the largest private bank in the world, has applied a robust customer onboarding system thanks to Regula’s comprehensive identity verification solutions.
- FREENOW, a Mobility Super App, employs a set of Regula solutions to enable proper taxi driver identity verification to secure its ride-hailing services.
- WizzAir and AirAsia use Regula solutions to expedite flight onboarding.
- The Portuguese Immigration and Border Service has facilitated travel document verification by developing a mobile app based on Regula Document Reader SDK.
- Pearson VUE, a global online testing giant, identifies users with the help of Regula technologies to grant admission to remotely administered professional exams.
"In this fiercely competitive market, it is imperative for all vendors to maintain a razor-sharp focus on delivering unwavering value to their users, ensuring that their services become indispensable components of daily operations," remarked Henry Patishman, Executive VP of Identity Verification Solutions at Regula. "Leveraging our deep-rooted expertise in both hardware and software, coupled with our strong and enduring connections within the forensic community, Regula has crafted a unique proposition. This combination of cutting-edge technology and forensic expertise allows us to deliver a deeply enriching experience for a wide range of applications to streamline onboarding and prevent identity fraud. Consequently, we have witnessed robust user adoption, a testament to our strategic investment in creating solutions that not only meet but exceed the expectations of our users in today’s dynamic environment."
For more information about Regula and its services, please visit Regula's website.
About Regula
With our 30+ years of experience in forensic research and the largest library of document templates in the world, we create breakthrough technologies in document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed.
Regula was named a Representative Vendor in the Gartner® Market Guide for Identity Verification in 2023.
Learn more at regulaforensics.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240228514546/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
1NCE Continues Growth and Expands Its Software, AI and Services Offering7.1.2026 14:15:00 CET | Press release
In 2025 1NCE added another 10 million endpoints to its foundational IoT platform; now manages 40+ million intelligent products for 30,000 customers in 17 industries. Introduces new software, 1NCE Insights, the AI + IoT fusion of intelligence from its network that gives analytics and benchmark data on how customers can better setup, manage and optimize their device estates. 1NCE, a company offering a plug-and-play platform for creating and managing the world’s best IoT products, reports another strong growth year, adding another 10 million endpoints. The company now manages 40+ million intelligent products for 30,000+ customers across 17 industries. 1NCE’s software and connectivity platform has become a new industry standard, delivering hassle-free IoT in 170+ countries and regions. The company has a unique vantage point in the IoT ecosystem, with four billion data records per day collected through 250+ streams on the world’s largest IoT network in the cloud. The company launched a new
Prudentia Sciences Announces Series A Led by McKesson Ventures, Accelerating Due Diligence for Life Sciences Dealmaking7.1.2026 14:00:00 CET | Press release
Prudentia Sciences, a pioneer in AI-native due diligence for life sciences dealmaking, today announced that it has secured $20 million in Series A financing. The round was led by McKesson Ventures with participation from SignalFire. Existing investors include Iaso Ventures, Virtue and GV. This brings the company’s total funding to $27 million, following a $7 million seed round in 2024. Prudentia Sciences provides an AI-native platform that enables pharma companies, biotechs, and financial institutions to evaluate breakthrough medicines with unprecedented speed and rigor. By synthesizing complex clinical signals into actionable insights, Prudentia accelerates deal throughput and provides strategic leverage for acquisition, licensing, or investment decisions made by business development, investment, and diligence teams. The company’s human-in-the-loop approach orchestrates seamless collaboration between buyers, sellers, and intermediaries. This ensures a secure, compliant infrastructure
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
